Net Loss Per Share Allocable to Common Stockholders (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Computation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share allocable to common stockholders for the three and nine months ended September 30, 2025 and 2024 (in thousands, except share and per-share data):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Numerator:
Net loss	$	(35,902)	$	(24,183)	$	(37,726)	$	(67,171)



Denominator:
Weighted-average common shares outstanding - basic and diluted	26,002,892		21,471,408		25,962,302		14,561,613



Net loss per share allocable to common stockholders:
Basic and diluted	$	(1.38)	$	(1.13)	$	(1.45)	$	(4.61)

Schedule of Potential Dilutive Shares of Common Stock Excluded from the Computation of the Diluted Net Loss Per Share Allocable to Common Stockholders

The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net loss per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Common stock options and restricted stock units	2,956,910	2,420,400	2,956,910	2,420,400
Warrants to purchase common stock	692,523	974,954	692,523	974,954
Series A Preferred Stock	4,026,346	5,544,719	4,026,346	5,544,719

Series B Preferred Stock	437,927	437,927	437,927	437,927
Total	8,113,706	9,378,000	8,113,706	9,378,000

Cartesian Therapeutics, Inc. 10-Q